{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:19:37Z","timestamp":1788013177220,"version":"build-2784847793"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"DOI":"10.1007\/s11899-026-00787-0","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T01:37:16Z","timestamp":1787967436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real World Data and Its Impact on the Management of Plasma Cell Dyscrasias"],"prefix":"10.1007","volume":"21","author":[{"given":"Naveen","family":"Subramanian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel M.","family":"Rubinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"787_CR1","unstructured":"Keyes D, Varacallo MA. Evidence-based medicine. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2026."},{"issue":"5","key":"787_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.13107\/jocr.2025.v15.i05.5534","volume":"15","author":"A Vatkar","year":"2025","unstructured":"Vatkar A, Kale S, Shyam A, Srivastava S. Understanding the levels of evidence in medical research. J Orthop Case Rep. 2025;15(5):6\u20139.","journal-title":"J Orthop Case Rep"},{"issue":"13","key":"787_CR3","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/1471-0528.15199","volume":"125","author":"E Hariton","year":"2018","unstructured":"Hariton E, Locascio JJ. Randomised controlled trials - the gold standard for effectiveness research: Study design: randomised controlled trials. BJOG. 2018;125(13):1716.","journal-title":"BJOG"},{"issue":"1","key":"787_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.imr.2019.01.001","volume":"8","author":"AS Ahuja","year":"2019","unstructured":"Ahuja AS. Should RCT\u2019s be used as the gold standard for evidence based medicine? Integr Med Res. 2019;8(1):31\u20132.","journal-title":"Integr Med Res"},{"key":"787_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.amjcard.2020.05.011","volume":"129","author":"JB Kostis","year":"2020","unstructured":"Kostis JB, Dobrzynski JM. Limitations of Randomized Clinical Trials. Am J Cardiol. 2020;129:109\u201315.","journal-title":"Am J Cardiol"},{"key":"787_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s13063-015-1023-4","volume":"16","author":"T Kennedy-Martin","year":"2015","unstructured":"Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;16:495.","journal-title":"Trials"},{"issue":"1","key":"787_CR7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13023-017-0755-5","volume":"13","author":"D Whicher","year":"2018","unstructured":"Whicher D, Philbin S, Aronson N. An overview of the impact of rare disease characteristics on research methodology. Orphanet J Rare Dis. 2018;13(1):14.","journal-title":"Orphanet J Rare Dis"},{"key":"787_CR8","doi-asserted-by":"publisher","first-page":"100913","DOI":"10.1016\/j.blre.2021.100913","volume":"53","author":"BA Derman","year":"2022","unstructured":"Derman BA, Belli AJ, Battiwalla M, et al. Reality check: Real-world evidence to support therapeutic development in hematologic malignancies. Blood Rev. 2022;53:100913.","journal-title":"Blood Rev"},{"issue":"2","key":"787_CR9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1177\/1932296819832661","volume":"14","author":"DC Klonoff","year":"2020","unstructured":"Klonoff DC. The new FDA real-world evidence program to support development of drugs and biologics. J Diabetes Sci Technol. 2020;14(2):345\u20139.","journal-title":"J Diabetes Sci Technol"},{"issue":"3","key":"787_CR10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/cpt.3713","volume":"118","author":"G Candore","year":"2025","unstructured":"Candore G, Martin C, Mills MJ, et al. FRAME: Framework for real-world evidence assessment to mitigate evidence uncertainties for efficacy\/effectiveness - an evaluation of regulatory and health technology assessment decision making. Clin Pharmacol Ther. 2025;118(3):649\u201361.","journal-title":"Clin Pharmacol Ther"},{"key":"787_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/JMDH.S160029","volume":"11","author":"VB Katkade","year":"2018","unstructured":"Katkade VB, Sanders KN, Zou KH. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. J Multidiscip Healthc. 2018;11:295\u2013304.","journal-title":"J Multidiscip Healthc"},{"issue":"13","key":"787_CR12","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1200\/JCO-24-01730","volume":"43","author":"DK Hansen","year":"2025","unstructured":"Hansen DK, Peres LC, Dima D, et al. Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed\/refractory multiple myeloma. J Clin Oncol. 2025;43(13):1597\u2013609.","journal-title":"J Clin Oncol"},{"issue":"9","key":"787_CR13","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","volume":"56","author":"S Skerget","year":"2024","unstructured":"Skerget S, Penaherrera D, Chari A, et al. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. Nat Genet. 2024;56(9):1878\u201389.","journal-title":"Nat Genet"},{"issue":"29","key":"787_CR14","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D\u2019agostino","year":"2022","unstructured":"D\u2019agostino M, Cairns DA, Lahuerta JJ, et al. Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40(29):3406\u201318.","journal-title":"J Clin Oncol"},{"issue":"21","key":"787_CR15","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1182\/blood.V124.21.3421.3421","volume":"124","author":"F Canzian","year":"2014","unstructured":"Canzian F, Beider K, Buda G, et al. The International Multiple Myeloma Research (IMMEnSE) Consortium: genetics of multiple myeloma risk and prognosis. Blood. 2014;124(21):3421.","journal-title":"Blood"},{"issue":"1","key":"787_CR16","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1038\/s41598-025-34147-4","volume":"16","author":"EM Babu","year":"2026","unstructured":"Babu EM, Fermahan S, Bowen J, et al. Real-world analysis of multiple myeloma treatments in England using the Cancer Analysis System registry. Sci Rep. 2026;16(1):4055.","journal-title":"Sci Rep"},{"issue":"1","key":"787_CR17","doi-asserted-by":"publisher","first-page":"24782","DOI":"10.1038\/s41598-025-03391-z","volume":"15","author":"C Shan","year":"2025","unstructured":"Shan C, Zhang Y, Zhang X, Li L, Chen Y, Liu Y. Real-world FDA database analysis unveiling cardiovascular adverse events associated with bispecific T cell engagers in multip myeloma. Sci Rep. 2025;15(1):24782.","journal-title":"Sci Rep"},{"issue":"2","key":"787_CR18","doi-asserted-by":"publisher","first-page":"e008518","DOI":"10.1136\/jitc-2023-008518","volume":"12","author":"A Sayed","year":"2024","unstructured":"Sayed A, Munir M, Ghazi SM, et al. Cardiovascular toxicities associated with bispecific T-cell engager therapy. J Immunother Cancer. 2024;12(2):e008518.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"787_CR19","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","volume":"132","author":"BA Walker","year":"2018","unstructured":"Walker BA, Mavrommatis K, Wardell CP, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018;132(6):587\u201397.","journal-title":"Blood"},{"issue":"1","key":"787_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41408-025-01253-5","volume":"15","author":"JTD Souto Filho","year":"2025","unstructured":"Souto Filho JTD, Cantadori LO, Crusoe EQ, Hungria V, Maiolino A. Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis. Blood Cancer J. 2025;15(1):37.","journal-title":"Blood Cancer J"},{"key":"787_CR21","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3389\/fphar.2018.00430","volume":"9","author":"JL Li","year":"2018","unstructured":"Li JL, Fan GY, Liu YJ, et al. Long-term efficacy of maintenance therapy for multiple myeloma: a quantitative synthesis of 22 randomized controlled trials. Front Pharmacol. 2018;9:430.","journal-title":"Front Pharmacol"},{"issue":"11","key":"787_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41408-018-0141-0","volume":"8","author":"PG Richardson","year":"2018","unstructured":"Richardson PG, San Miguel JF, Moreau P, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018;8(11):109.","journal-title":"Blood Cancer J"},{"issue":"6","key":"787_CR23","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bjh.14514","volume":"176","author":"JA Snowden","year":"2017","unstructured":"Snowden JA, Greenfield DM, Bird JM, et al. Guidelines for screening and management of late and long-term consequences of myeloma and its treatment. Br J Haematol. 2017;176(6):888\u2013907.","journal-title":"Br J Haematol"},{"issue":"10","key":"787_CR24","doi-asserted-by":"publisher","first-page":"e408","DOI":"10.1016\/S2352-3026(15)00151-9","volume":"2","author":"SF Huntington","year":"2015","unstructured":"Huntington SF, Weiss BM, Vogl DT, et al. Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Haematol. 2015;2(10):e408\u201316.","journal-title":"Lancet Haematol"},{"issue":"2","key":"787_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/ejh.12876","volume":"99","author":"D Robinson Jr","year":"2017","unstructured":"Robinson D Jr, Orlowski RZ, Stokes M, et al. Economic burden of relapsed or refractory multiple myeloma: Results from an international trial. Eur J Haematol. 2017;99(2):119\u201332.","journal-title":"Eur J Haematol"},{"issue":"10297","key":"787_CR26","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324.","journal-title":"Lancet"},{"issue":"1","key":"787_CR27","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41408-024-01167-8","volume":"14","author":"GG Fortuna","year":"2024","unstructured":"Fortuna GG, Banerjee R, Savid-Frontera C, et al. Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. Blood cancer J. 2024;14(1):180.","journal-title":"Blood cancer J"},{"issue":"1","key":"787_CR28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","volume":"8","author":"KA Frerichs","year":"2024","unstructured":"Frerichs KA, Verkleij CP, Mateos MV, et al. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation. Blood Adv. 2024;8(1):194\u2013206.","journal-title":"Blood Adv"},{"issue":"1","key":"787_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-025-01282-0","volume":"15","author":"M Mohan","year":"2025","unstructured":"Mohan M, Szabo A, Cheruvalath H, et al. Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma. Blood Cancer J. 2025;15(1):74.","journal-title":"Blood Cancer J"},{"issue":"10214","key":"787_CR30","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","volume":"394","author":"M Attal","year":"2019","unstructured":"Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096\u2013107.","journal-title":"Lancet"},{"issue":"14","key":"787_CR31","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319\u201331.","journal-title":"N Engl J Med"},{"key":"787_CR32","doi-asserted-by":"publisher","first-page":"1400101","DOI":"10.3389\/fimmu.2024.1400101","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Shan C, Zhang X, Liu Y, Xia Y, Wang Y. Cardiovascular adverse events associated with targeted therapies for multiple myeloma: a pharmacovigilance study. Front Immunol. 2024;15:1400101.","journal-title":"Front Immunol"},{"issue":"5","key":"787_CR33","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00228-025-03824-8","volume":"81","author":"MA Barbieri","year":"2025","unstructured":"Barbieri MA, Russo G, Cicala G, et al. Unveiling cardiovascular and respiratory toxicities with monoclonal antibodies in multiple myeloma: disproportionality analysis from the FDA Adverse Event Reporting System. Eur J Clin Pharmacol. 2025;81(5):755\u201370.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"787_CR34","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","volume":"31","author":"SZ Usmani","year":"2025","unstructured":"Usmani SZ, Facon T, Hungria V, et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nat Med. 2025;31(4):1195\u2013202. https:\/\/doi.org\/10.1038\/s41591-024-03485-7. Epub 2025 Feb 5. Erratum in: Nat Med. 2025;31(4):1366.","journal-title":"Nat Med"},{"issue":"7","key":"787_CR35","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1001\/jamaoncol.2015.6487","volume":"2","author":"JM Unger","year":"2016","unstructured":"Unger JM, Barlow WE, Ramsey SD, LeBlanc M, Blanke CD, Hershman DL. The scientific impact of positive and negative phase 3 cancer clinical trials. JAMA Oncol. 2016;2(7):875\u201381.","journal-title":"JAMA Oncol"},{"issue":"8","key":"787_CR36","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"1","key":"787_CR37","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1182\/bloodadvances.2023010894","volume":"8","author":"LC Peres","year":"2024","unstructured":"Peres LC, Oswald LB, Dillard CM, et al. Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy. Blood Adv. 2024;8(1):251\u20139.","journal-title":"Blood Adv"},{"issue":"1","key":"787_CR38","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41408-025-01419-1","volume":"15","author":"M Bhutani","year":"2025","unstructured":"Bhutani M, Habib A, Vegel A, et al. Outcomes of CAR T-Cell therapy in relapsed\/refractory multiple myeloma by race: a multicenter real-world study. Blood Cancer J. 2025;15(1):200.","journal-title":"Blood Cancer J"},{"issue":"1","key":"787_CR39","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41408-026-01489-9","volume":"16","author":"CM Dillard","year":"2026","unstructured":"Dillard CM, Lee H, Kalariya N, et al. Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed\/refractory multiple myeloma. Blood Cancer J. 2026;16(1):59.","journal-title":"Blood Cancer J"},{"issue":"11","key":"787_CR40","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Sidana S, Peres LC, et al. Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium. J Clin Oncol. 2023;41(11):2087\u201397.","journal-title":"J Clin Oncol"},{"issue":"2","key":"787_CR41","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1182\/blood.2024026216","volume":"146","author":"S Sidana","year":"2025","unstructured":"Sidana S, Ahmed N, Akhtar OS, et al. Standard-of-care idecabtagene vicleucel for relapsed\/refractory multiple myeloma. Blood. 2025;146(2):167\u201377.","journal-title":"Blood"},{"issue":"7","key":"787_CR42","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/ajh.26583","volume":"97","author":"J Du","year":"2022","unstructured":"Du J, Wei R, Jiang S, et al. CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed\/refractory multiple myeloma, including cases with poor performance status. Am J Hematol. 2022;97(7):933\u201341.","journal-title":"Am J Hematol"},{"key":"787_CR43","unstructured":"Kamboj I, Habib A, Chang D et al. Real-world efficacy outcomes of ciltacabtagene autoleucel in relapsed refractory multiple myeloma: a comparative study with the cartitude-1 trial. Clin Lymphoma Myeloma Leuk 2025;S2152-2650(25)04226-0."},{"issue":"1","key":"787_CR44","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2024025945","volume":"145","author":"S Sidana","year":"2025","unstructured":"Sidana S, Patel KK, Peres LC, et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Blood. 2025;145(1):85\u201397.","journal-title":"Blood"},{"key":"787_CR45","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1182\/blood-2023-187583","volume":"142","author":"N Subramanian","year":"2023","unstructured":"Subramanian N, Gurumurthi A, Pasvolsky O, et al. Attrition after referral for Chimeric Antigen Receptor T-Cell (CAR-T) products in Multiple Myeloma (MM). Blood. 2023;142:3794.","journal-title":"Blood"},{"issue":"6","key":"787_CR46","first-page":"350","volume":"29","author":"KR Reyes","year":"2023","unstructured":"Reyes KR, Huang CY, Lo M, et al. Safety and efficacy of BCMA CAR-T cell therapy in older patients with multiple myeloma. Transpl Cell Ther. 2023;29(6):350\u20135.","journal-title":"Transpl Cell Ther"},{"issue":"5","key":"787_CR47","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00277-023-05163-z","volume":"102","author":"R W\u00e4sch","year":"2023","unstructured":"W\u00e4sch R, Str\u00fcssmann T, Wehr C, et al. Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis. Ann Hematol. 2023;102(5):1269\u201370.","journal-title":"Ann Hematol"},{"issue":"22","key":"787_CR48","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104\u201315.","journal-title":"N Engl J Med"},{"key":"787_CR49","doi-asserted-by":"publisher","first-page":"113921","DOI":"10.1016\/j.ejca.2024.113921","volume":"201","author":"N Abildgaard","year":"2024","unstructured":"Abildgaard N, Anttila P, Waage A, et al. Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registries. Eur J Cancer. 2024;201:113921.","journal-title":"Eur J Cancer"},{"issue":"1","key":"787_CR50","doi-asserted-by":"publisher","first-page":"77","DOI":"10.20892\/j.issn.2095-3941.2022.0612","volume":"20","author":"H Fan","year":"2023","unstructured":"Fan H, Wang W, Zhang Y, et al. Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study. Cancer Biol Med. 2023;20(1):77\u201387.","journal-title":"Cancer Biol Med"},{"issue":"10192","key":"787_CR51","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394(10192):29\u201338.","journal-title":"Lancet"},{"issue":"4","key":"787_CR52","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390(4):301\u201313.","journal-title":"N Engl J Med"},{"issue":"9","key":"787_CR53","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3390\/cancers17091389","volume":"17","author":"K Suzuki","year":"2025","unstructured":"Suzuki K, Fujimori Y, Sakai C, Tsuchiya H, Koroki Y. Real-world treatment outcomes of different sequencing options with daratumumab, lenalidomide, and dexamethasone in patients with transplant-ineligible multiple myeloma in Japan. Cancers (Basel). 2025;17(9):1389.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"787_CR54","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.1016\/j.clml.2025.11.003","volume":"26","author":"G Bertuglia","year":"2026","unstructured":"Bertuglia G, Seneca E, Corbett T, et al. Evaluating the real-world value of daratumumab addition to multiple myeloma induction therapy by real-world minimal residual disease assessment and extended genetic profiling. Clin Lymphoma Myeloma Leuk. 2026;26(2):e188-e200.e5.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"787_CR55","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266\u201375.","journal-title":"Leukemia"},{"issue":"1","key":"787_CR56","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41408-024-01120-9","volume":"14","author":"NS Joseph","year":"2024","unstructured":"Joseph NS, Kaufman JL, Gupta VA, et al. Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients. Blood Cancer J. 2024;14(1):159.","journal-title":"Blood Cancer J"},{"issue":"21","key":"787_CR57","doi-asserted-by":"publisher","first-page":"e70308","DOI":"10.1002\/cam4.70308","volume":"13","author":"DK Hansen","year":"2024","unstructured":"Hansen DK, Gautam S, Lafeuille MH, et al. Comparison of time to next treatment or death between front-line daratumumab, lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) among transplant-ineligible patients with multiple myeloma. Cancer Med. 2024;13(21):e70308.","journal-title":"Cancer Med"},{"key":"787_CR58","unstructured":"Ailawadhi S, Anderson LD Jr, Dhakal B, Shune L, Sborov DW, Hansen DK. Optimizing selection of bridging therapies prior to car-t therapy administration for multiple myeloma: clinical pearls from an expert roundtable. Clin Lymphoma Myeloma Leuk 2025;S2152-2650(25)00268-X."},{"issue":"5","key":"787_CR59","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/j.clml.2024.01.014","volume":"24","author":"S Ailawadhi","year":"2024","unstructured":"Ailawadhi S, Shune L, Wong SW, Lin Y, Patel K, Jagannath S. Optimizing the CAR T-cell therapy experience in multiple myeloma: clinical pearls from an expert roundtable. Clin Lymphoma Myeloma Leuk. 2024;24(5):e217\u201325.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"787_CR60","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41408-024-00993-0","volume":"14","author":"A Afrough","year":"2024","unstructured":"Afrough A, Hashmi H, Hansen DK, et al. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium. Blood Cancer J. 2024;14(1):63.","journal-title":"Blood Cancer J"},{"issue":"8","key":"787_CR61","first-page":"e5041","volume":"29","author":"A Zafar","year":"2023","unstructured":"Zafar A, Huang CY, Lo M, et al. Intensity of cyclophosphamide-based bridging therapy before chimeric antigen receptor T cell therapy in myeloma. Transpl Cell Ther. 2023;29(8):e5041\u20137.","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"787_CR62","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1158\/2643-3230.BCD-24-0118","volume":"6","author":"D Fandrei","year":"2025","unstructured":"Fandrei D, Seiffert S, Rade M, et al. Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed\/refractory multiple myeloma. Blood Cancer Discov. 2025;6(1):38\u201354.","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"787_CR63","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","volume":"13","author":"CJ Ferreri","year":"2023","unstructured":"Ferreri CJ, Hildebrandt MAT, Hashmi H, et al. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023;13(1):117.","journal-title":"Blood Cancer J"},{"key":"787_CR64","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1182\/blood-2025-2811","volume":"146","author":"S Scott","year":"2025","unstructured":"Scott S, Nooka A, Kaufman J, et al. Talquetamab bridging therapy for B-cell maturation antigen chimeric antigen receptor T-cell in Relapsed\/Refractory multiple myeloma. Blood. 2025;146:2811.","journal-title":"Blood"},{"key":"787_CR65","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1182\/blood-2024-202017","volume":"144","author":"B Dhakal","year":"2024","unstructured":"Dhakal B, Akhtar OS, Cowan AJ, et al. Talquetamab bridging: paving the way to B-cell maturation antigen (BCMA) CAR-T cell therapy in relapsed\/refractory multiple myeloma (RRMM). Blood. 2024;144:931.","journal-title":"Blood"},{"issue":"23","key":"787_CR66","doi-asserted-by":"publisher","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-21-0308","volume":"27","author":"SH Manjunath","year":"2021","unstructured":"Manjunath SH, Cohen AD, Lacey SF, et al. The safety of bridging radiation with Anti-BCMA CAR T-cell therapy for multiple myeloma. Clin Cancer Res. 2021;27(23):6580\u201390.","journal-title":"Clin Cancer Res"},{"key":"787_CR67","doi-asserted-by":"publisher","first-page":"109933","DOI":"10.1016\/j.radonc.2023.109933","volume":"189","author":"HS Ababneh","year":"2023","unstructured":"Ababneh HS, Yee AJ, Raje NS, et al. Radiation therapy as a bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapy. Radiother Oncol. 2023;189:109933.","journal-title":"Radiother Oncol"},{"key":"787_CR68","first-page":"1","volume":"2","author":"YL Hwa","year":"2025","unstructured":"Hwa YL, Doss D, Mangan PA, Faber MC, Catamero DD. Understanding the role and clinical management of bridging therapy during CAR T-Cell therapy for relapsed or refractory multiple myeloma. J Adv Pract Oncol. 2025;2:1\u20139.","journal-title":"J Adv Pract Oncol"},{"issue":"5","key":"787_CR69","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc3257","volume":"12","author":"GJ Morgan","year":"2012","unstructured":"Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12(5):335\u201348.","journal-title":"Nat Rev Cancer"},{"issue":"7339","key":"787_CR70","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","volume":"471","author":"MA Chapman","year":"2011","unstructured":"Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471(7339):467\u201372.","journal-title":"Nature"},{"issue":"15","key":"787_CR71","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412\u201320.","journal-title":"J Clin Oncol"},{"issue":"26","key":"787_CR72","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863\u20139.","journal-title":"J Clin Oncol"},{"issue":"5","key":"787_CR73","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.clml.2019.01.003","volume":"19","author":"SR Goldsmith","year":"2019","unstructured":"Goldsmith SR, Fiala MA, Dukeman J, et al. Next generation sequencing-based validation of the revised international staging system for multiple myeloma: an analysis of the MMRF CoMMpass study. Clin Lymphoma Myeloma Leuk. 2019;19(5):285\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"787_CR74","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41408-022-00611-x","volume":"12","author":"NH Abdallah","year":"2022","unstructured":"Abdallah NH, Binder M, Rajkumar SV, et al. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 2022;12(1):21.","journal-title":"Blood Cancer J"},{"issue":"1","key":"787_CR75","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1002\/hem3.33","volume":"8","author":"H Cho","year":"2024","unstructured":"Cho H, Kim K, Yoon SE, et al. Evaluation of the R2-ISS in real-world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202). Hemasphere. 2024;8(1):e33.","journal-title":"Hemasphere"},{"issue":"10","key":"787_CR76","doi-asserted-by":"publisher","first-page":"e20612","DOI":"10.1016\/j.heliyon.2023.e20612","volume":"9","author":"F Zhang","year":"2023","unstructured":"Zhang F, Wu Z, Sun S, Fu Y, Chen Y, Liu J. POEMS syndrome in the 21st century: A bibliometric analysis. Heliyon. 2023;9(10):e20612.","journal-title":"Heliyon"},{"issue":"12","key":"787_CR77","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1002\/ajh.27081","volume":"98","author":"A Dispenzieri","year":"2023","unstructured":"Dispenzieri A. POEMS syndrome: Update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(12):1934\u201350.","journal-title":"Am J Hematol"},{"issue":"23","key":"787_CR78","doi-asserted-by":"publisher","first-page":"7011","DOI":"10.3390\/jcm11237011","volume":"11","author":"M Bou Zerdan","year":"2022","unstructured":"Bou Zerdan M, George TI, Bunting ST, Chaulagain CP. Recent advances in the treatment and supportive care of POEMS syndrome. J Clin Med. 2022;11(23):7011.","journal-title":"J Clin Med"},{"issue":"9","key":"787_CR79","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1038\/s41375-018-0209-7","volume":"32","author":"M Gavriatopoulou","year":"2018","unstructured":"Gavriatopoulou M, Musto P, Caers J, et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018;32(9):1883\u201398.","journal-title":"Leukemia"},{"issue":"12","key":"787_CR80","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1136\/jnnp-2012-304874","volume":"84","author":"Y Sekiguchi","year":"2013","unstructured":"Sekiguchi Y, Misawa S, Shibuya K, et al. Ambiguous effects of anti-VEGF monoclonal antibody (bevacizumab) for POEMS syndrome. J Neurol Neurosurg Psychiatry. 2013;84(12):1346\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"787_CR81","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.clml.2021.10.007","volume":"22","author":"A Jurczyszyn","year":"2022","unstructured":"Jurczyszyn A, Castillo JJ, Olszewska-Szopa M, et al. POEMS syndrome: real world experience in diagnosis and systemic therapy\u2009\u2013\u2009108 patients multicenter analysis. Clin Lymphoma Myeloma Leuk. 2022;22(5):297\u2013304.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"787_CR82","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41375-019-0391-2","volume":"33","author":"H Zhao","year":"2019","unstructured":"Zhao H, Huang XF, Gao XM, et al. What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone? Leukemia. 2019;33(4):1023\u20139.","journal-title":"Leukemia"},{"issue":"2","key":"787_CR83","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/bjh.18400","volume":"200","author":"J Khwaja","year":"2023","unstructured":"Khwaja J, D\u2019Sa S, Lunn MP, Sive J. Evidence-based medical treatment of POEMS syndrome. Br J Haematol. 2023;200(2):128\u201336.","journal-title":"Br J Haematol"},{"issue":"25","key":"787_CR84","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","volume":"378","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstr\u00f6m\u2019s Macroglobulinemia. N Engl J Med. 2018;378(25):2399\u2013410.","journal-title":"N Engl J Med"},{"issue":"1","key":"787_CR85","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41408-023-00916-5","volume":"13","author":"WL Chan","year":"2023","unstructured":"Chan WL, Chong VCL, Wee IJY, et al. Efficacy and safety of front-line treatment regimens for Waldenstrom macroglobulinaemia: a systematic review and meta-analysis. Blood Cancer J. 2023;13(1):140.","journal-title":"Blood Cancer J"},{"key":"787_CR86","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.2147\/OTT.S191179","volume":"12","author":"YH Zheng","year":"2019","unstructured":"Zheng YH, Xu L, Cao C, et al. Rituximab-based combination therapy in patients with Waldenstr\u00f6m macroglobulinemia: a systematic review and meta-analysis. Onco Targets Ther. 2019;12:2751\u201366.","journal-title":"Onco Targets Ther"},{"issue":"18","key":"787_CR87","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1182\/blood-2008-08-174961","volume":"113","author":"P Morel","year":"2009","unstructured":"Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113(18):4163\u201370.","journal-title":"Blood"},{"issue":"11","key":"787_CR88","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1038\/s41375-019-0431-y","volume":"33","author":"E Kastritis","year":"2019","unstructured":"Kastritis E, Morel P, Duhamel A, et al. A revised international prognostic score system for Waldenstr\u00f6m\u2019s macroglobulinemia. Leukemia. 2019;33(11):2654\u201361.","journal-title":"Leukemia"},{"issue":"3","key":"787_CR89","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3904\/kjim.2019.367","volume":"36","author":"JH Cho","year":"2021","unstructured":"Cho JH, Shim JH, Yoon SE, et al. Real-world data on the survival outcome of patients with newly diagnosed Waldenstr\u00f6m macroglobulinemia. Korean J Intern Med. 2021;36(3):668\u201378.","journal-title":"Korean J Intern Med"},{"key":"787_CR90","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1182\/blood-2024-199276","volume":"144","author":"S D\u2019Sa","year":"2024","unstructured":"D\u2019Sa S, Dimopoulos MA, Jurczak W, et al. Long-term clinical outcomes in patients with Waldenstr\u00f6m macroglobulinemia (WM) who received zanubrutinib in the phase 3 ASPEN study: a report from the zanubrutinib extension study. Blood. 2024;144:3031.","journal-title":"Blood"},{"issue":"1","key":"787_CR91","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41408-025-01415-5","volume":"15","author":"KL Chohan","year":"2025","unstructured":"Chohan KL, Gensini L, Seif S, et al. Long-term outcomes and treatment patterns in Waldenstr\u00f6m macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy. Blood Cancer J. 2025;15(1):211.","journal-title":"Blood Cancer J"},{"issue":"1","key":"787_CR92","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","volume":"385","author":"E Kastritis","year":"2021","unstructured":"Kastritis E, Palladini G, Minnema MC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385(1):46\u201358.","journal-title":"N Engl J Med"},{"issue":"1","key":"787_CR93","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41375-021-01317-y","volume":"36","author":"A Dispenzieri","year":"2022","unstructured":"Dispenzieri A, Kastritis E, Wechalekar AD, et al. A randomized phase 3 study of ixazomib-dexamethasone versus physician\u2019s choice in relapsed or refractory AL amyloidosis. Leukemia. 2022;36(1):225\u201335.","journal-title":"Leukemia"},{"issue":"3","key":"787_CR94","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/ejh.14348","volume":"114","author":"M Stalker","year":"2025","unstructured":"Stalker M, Garfall A, Cohen A, et al. Safety and efficacy of teclistamab in patients with relapsed or refractory AL amyloidosis. Eur J Haematol. 2025;114(3):443\u20137.","journal-title":"Eur J Haematol"},{"key":"787_CR95","doi-asserted-by":"publisher","first-page":"7562","DOI":"10.1200\/JCO.2025.43.16_suppl.7562","volume":"43","author":"V Mico","year":"2025","unstructured":"Mico V, Wu X, Toskic D, et al. Teclistamab in relapsed\/refractory systemic AL amyloidosis. J Clin Oncol. 2025;43:7562.","journal-title":"J Clin Oncol"},{"key":"787_CR96","doi-asserted-by":"publisher","first-page":"108267","DOI":"10.1016\/j.leukres.2026.108267","volume":"167","author":"S Huang","year":"2026","unstructured":"Huang S, Luo J, Yu G, Zhu Y. Efficacy and safety of BCMA-directed bispecific antibodies in relapsed and\/or refractory systemic AL amyloidosis: A systematic review and meta-analysis. Leuk Res. 2026;167:108267.","journal-title":"Leuk Res"},{"issue":"6","key":"787_CR97","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.3390\/cancers15061710","volume":"15","author":"E Lebel","year":"2023","unstructured":"Lebel E, Kastritis E, Palladini G, et al. Venetoclax in relapse\/refractory AL Amyloidosis-a multicenter international retrospective real-world study. Cancers (Basel). 2023;15(6):1710.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"787_CR98","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/13506129.2024.2366806","volume":"31","author":"D Dima","year":"2024","unstructured":"Dima D, Hughes M, Orland M, et al. Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy. Amyloid. 2024;31(3):195\u2013201.","journal-title":"Amyloid"},{"issue":"1","key":"787_CR99","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41408-020-00397-w","volume":"11","author":"VJ Premkumar","year":"2021","unstructured":"Premkumar VJ, Lentzsch S, Pan S, et al. Venetoclax induces deep hematologic remissions in t(11;14) relapsed\/refractory AL amyloidosis. Blood Cancer J. 2021;11(1):10.","journal-title":"Blood Cancer J"},{"issue":"7","key":"787_CR100","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jama.2020.9151","volume":"325","author":"K Yadav","year":"2021","unstructured":"Yadav K, Lewis RJ. Immortal Time Bias in Observational Studies. JAMA. 2021;325(7):686\u20137.","journal-title":"JAMA"},{"issue":"18","key":"787_CR101","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","volume":"22","author":"A Dispenzieri","year":"2004","unstructured":"Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751\u20137.","journal-title":"J Clin Oncol"},{"issue":"9","key":"787_CR102","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989\u201395.","journal-title":"J Clin Oncol"},{"issue":"17","key":"787_CR103","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","volume":"121","author":"AD Wechalekar","year":"2013","unstructured":"Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420\u20137.","journal-title":"Blood"},{"issue":"4","key":"787_CR104","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1200\/JCO-25-02558","volume":"44","author":"J Khwaja","year":"2026","unstructured":"Khwaja J, Kirkwood AA, Milani P, et al. New validated staging system for light chain (AL) amyloidosis with stage IIIC defining ultra-poor risk: AL international staging system. J Clin Oncol. 2026;44(4):311\u201320.","journal-title":"J Clin Oncol"},{"issue":"22","key":"787_CR105","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1182\/blood-2012-07-445304","volume":"120","author":"N Leung","year":"2012","unstructured":"Leung N, Bridoux F, Hutchison CA, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012;120(22):4292\u20135.","journal-title":"Blood"},{"issue":"15","key":"787_CR106","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","volume":"124","author":"G Palladini","year":"2014","unstructured":"Palladini G, Hegenbart U, Milani P, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124(15):2325\u201332.","journal-title":"Blood"},{"issue":"20","key":"787_CR107","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1056\/NEJMra1810907","volume":"384","author":"N Leung","year":"2021","unstructured":"Leung N, Bridoux F, Nasr SH. Monoclonal Gammopathy of Renal Significance. N Engl J Med. 2021;384(20):1931\u201341.","journal-title":"N Engl J Med"},{"issue":"1","key":"787_CR108","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s10238-025-01646-7","volume":"25","author":"P Esposito","year":"2025","unstructured":"Esposito P, Macci\u00f2 L, Cagnetta A, et al. Monoclonal gammopathy of renal significance (MGRS): retrospective monocentric analysis of clinical outcomes and treatment strategies. Clin Exp Med. 2025;25(1):118.","journal-title":"Clin Exp Med"},{"issue":"7","key":"787_CR109","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/ajh.26566","volume":"97","author":"A Gozzetti","year":"2022","unstructured":"Gozzetti A, Guarnieri A, Zamagni E, et al. Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors. Am J Hematol. 2022;97(7):877\u201384.","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"787_CR110","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1182\/blood-2024-198929","volume":"144","author":"F Cottini","year":"2024","unstructured":"Cottini F, Rodriguez AMA, Sweiss K, et al. Real-World Outcomes of Monoclonal Gammopathy of Renal Significance (MGRS) in the Era of Novel Therapies. Blood. 2024;144(Supplement 1):3298.","journal-title":"Blood"},{"issue":"Supplement 1","key":"787_CR111","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood-2025-579","volume":"146","author":"D Bhutani","year":"2025","unstructured":"Bhutani D, Chakraborty R, Hughes M, et al. Isatuximab for the treatment of monoclonal gammopathy of renal significance (MGRS): Results from a prospective multicenter Phase 2 trial. Blood. 2025;146(Supplement 1):579.","journal-title":"Blood"},{"issue":"11","key":"787_CR112","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3390\/curroncol32110629","volume":"32","author":"PM Ellis","year":"2025","unstructured":"Ellis PM, Long L, Coschi CH, Sathiyapalan A. A narrative review of the strengths and limitations of real-world evidence in comparison to randomized clinical trials: what are the opportunities in thoracic oncology for real-world evidence to shine? Curr Oncol. 2025;32(11):629.","journal-title":"Curr Oncol"},{"issue":"3","key":"787_CR113","first-page":"368","volume":"22","author":"S de Lusignan","year":"2015","unstructured":"de Lusignan S, Crawford L, Munro N. Creating and using real-world evidence to answer questions about clinical effectiveness. J Innov Health Inf. 2015;22(3):368\u201373.","journal-title":"J Innov Health Inf"},{"issue":"3","key":"787_CR114","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/jcph.1989","volume":"62","author":"Y Franchetti","year":"2022","unstructured":"Franchetti Y. Use of propensity scoring and its application to real-world data: advantages, disadvantages, and methodological objectives explained to researchers without using mathematical equations. J Clin Pharmacol. 2022;62(3):304\u201319.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"787_CR115","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/10428194.2018.1459609","volume":"60","author":"S Kumar","year":"2019","unstructured":"Kumar S, Durie B, Nahi H, et al. Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma. Leuk Lymphoma. 2019;60(1):163\u201371.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"787_CR116","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s11523-026-01209-0","volume":"21","author":"YC Wang","year":"2026","unstructured":"Wang YC, Li PH, Lin CH, Su YC, Teng CJ. Elranatamab versus teclistamab in relapsed and refractory multiple myeloma: a real-world propensity score-matched study. Target Oncol. 2026;21(2):227\u201335.","journal-title":"Target Oncol"},{"issue":"1","key":"787_CR117","doi-asserted-by":"publisher","first-page":"90590","DOI":"10.5662\/wjm.v14.i1.90590","volume":"14","author":"MYQ Liau","year":"2024","unstructured":"Liau MYQ, Toh EQ, Muhamed S, Selvakumar SV, Shelat VG. Can propensity score matching replace randomized controlled trials? World J Methodol. 2024;14(1):90590.","journal-title":"World J Methodol"},{"issue":"7","key":"787_CR118","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1056\/NEJMsb1901642","volume":"382","author":"R Collins","year":"2020","unstructured":"Collins R, Bowman L, Landray M, Peto R. The magic of randomization versus the myth of real-world evidence. N Engl J Med. 2020;382(7):674\u20138.","journal-title":"N Engl J Med"},{"key":"787_CR119","unstructured":"US Food and Drug Administration. Framework for FDA\u2019s real world evidence program. Updated December 2018. Available at: https:\/\/www.fda.gov\/downloads\/ScienceResearch\/SpecialTopics\/RealWorldEvidence\/UCM627769.pdf. 2019 Jan 30."},{"issue":"11","key":"787_CR120","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1200\/JCO.23.01277","volume":"42","author":"F Maura","year":"2024","unstructured":"Maura F, Rajanna AR, Ziccheddu B, et al. Genomic classification and individualized prognosis in multiple myeloma. J Clin Oncol. 2024;42(11):1229\u201340.","journal-title":"J Clin Oncol"},{"issue":"12","key":"787_CR121","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1078-0432.CCR-21-3430","volume":"28","author":"C Guerrero","year":"2022","unstructured":"Guerrero C, Puig N, Cedena MT, et al. A machine learning model based on tumor and immune biomarkers to predict undetectable mrd and survival outcomes in multiple myeloma. Clin Cancer Res. 2022;28(12):2598\u2013609.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"787_CR122","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1038\/s41591-026-04304-x","volume":"32","author":"F Chabrun","year":"2026","unstructured":"Chabrun F, Schwartz DE, Gentile S, et al. Enhanced dynamic risk stratification of smoldering multiple myeloma. Nat Med. 2026;32(5):1745\u201353.","journal-title":"Nat Med"},{"issue":"13","key":"787_CR123","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.2217\/fon-2019-0013","volume":"15","author":"C Costello","year":"2019","unstructured":"Costello C, Davies FE, Cook G, et al. INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. Future Oncol. 2019;15(13):1411\u201328.","journal-title":"Future Oncol"},{"issue":"1","key":"787_CR124","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12874-024-02227-0","volume":"24","author":"N Aoki","year":"2024","unstructured":"Aoki N, Chen PY, Chen W, et al. The establishment of a multiple myeloma clinical registry in the Asia-Pacific region: The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR). BMC Med Res Methodol. 2024;24(1):102.","journal-title":"BMC Med Res Methodol"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00787-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-026-00787-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00787-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:03:15Z","timestamp":1788012195000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-026-00787-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":124,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["787"],"URL":"https:\/\/doi.org\/10.1007\/s11899-026-00787-0","relation":{},"ISSN":["1558-822X"],"issn-type":[{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"3 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"19"}}